Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT-CABG: XC001 adjunct to CABG in coronary artery disease with left ventricular dysfunction
2025-521325-33-00Phase 2Completed
- Sponsor
- XyloCor Therapeutics
- Start
- Nov 2025
- Modality
- Gene Therapies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing XC001 + CABG with Placebo + CABG (2 arms). Primary endpoint: Change from baseline in treated myocardial segments on CMR at Weeks 12 and 26. Started Nov 2025; status: completed.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2025-521325-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521325-33-00.